Theratechnologies Engages in Exclusive Acquisition Talks

The latest announcement is out from Theratechnologies ( (TSE:TH) ).

On April 11, 2025, Theratechnologies Inc. announced it is in exclusive discussions with a potential acquiror for the sale of the company, following a rejected proposal from Future Pak, LLC. The company has formed a special committee to evaluate acquisition proposals, with Barclays Capital Inc. and Fasken Martineau DuMoulin LLP as advisors. The outcome of these discussions could significantly impact Theratechnologies’ strategic direction and shareholder interests.

Spark’s Take on TSE:TH Stock

According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.

Theratechnologies faces significant challenges with profitability and high financial leverage, which weigh heavily on the stock’s attractiveness. While there are noteworthy improvements in FDA approvals and strategic partnerships, these are overshadowed by financial and technical weaknesses. Investors should remain cautious and monitor ongoing operational adjustments and financial stability improvements.

To see Spark’s full report on TSE:TH stock, click here.

More about Theratechnologies

Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care.

YTD Price Performance: 39.67%

Average Trading Volume: 2,864,303

Technical Sentiment Signal: Sell

Current Market Cap: $118.9M

Learn more about TH stock on TipRanks’ Stock Analysis page.